Raphael Hofstein is listed as a director on 2 SEC Form D filings by 2 issuers between Dec 2021 and Oct 2022: Scopus BioPharma Inc. (New York, NY — pharmaceuticals — 2021; $9.75M reported sold to 24 investors) and Duet BioTherapeutics Inc. (Pasadena, CA — biotechnology — 2022; $230K reported sold to 17 investors).
What this means 2 separate companies raised money with this person listed as director. Across those companies the filings report $9.98M sold in total.
1 of the issuers belongs to the sponsor group Growth And Emerging (3 issuers, $14.9M reported sold, 2012–2025).
What this means A sponsor group is one team that sets up a new company for each deal. Growth And Emerging has 3 companies on file and $14.9M reported sold in total — the group page shows the whole track record in one place.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 2 public filings for Raphael Hofstein and found 4 differences: Form D filed 17 days after the first sale; No amendment in the last 12 months on an offering that may still be open; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.